


HEPATOCELLULAR CANCER BIOMARKERS

For General Chemistry Analyzers

Diazyme offers sensitive and specific markers for Hepatocellular Cancer (HCC) for use on conventional clinical chemistry instrumentation. The assays include the traditional HCC markers, AFP and CEA as well as AFU an emerging marker which studies suggest may be a sensitive early indication of HCC which also aids in the detection of tumor size.¹⁻³ Diazyme's suite of HCC markers all feature excellent performance, fully liquid stable formulation, rapid test results and all at a low cost per test. All of Diazyme's HCC assay kits are readily adaptable to a wide range of open clinical chemistry analyzers and both calibrator and control are available for added convenience.

ZERO IN ON HCC WITH DIAZYME'S CANCER PANEL

***α -Fetoprotein
(AFP)****



***Carcinoembryonic
Antigen (CEA)****

***α -L-Fucosidase
(AFU)****

- *Accurate and precise*
- *Rapid results*
- *Low cost per test*

CE
USA: For Research Use Only



INNOVATIONS IN CLINICAL DIAGNOSTICS

HEPATOCELLULAR CANCER BIOMARKERS

	Carcinoembryonic Antigen (CEA)	α-Fetoprotein (AFP)	α-L-Fucosidase (AFU)
Method	Latex Enhanced Immunoturbidimetric Assay	Latex Enhanced Immunoturbidimetric Assay	Enzymatic (Kinetic assay monitoring at 405 nm of the enzymatic cleavage of a synthetic substrate)
Sample Type & Volume	• Serum Sample Volume 25 μ L	• Serum • Plasma Sample Volume 7 μ L	• Serum Sample Volume 25 μ L
Method Comparison	N = 56 Slope = 1.077 R ² = 0.839	N = 46 y-intercept = 2.0 Slope = 0.932 R ² = 0.894	y-intercept = 1.0788 Slope = -4.651 R ² = 0.998
Precision	Within-Run % CV: <5.22%	Within-Run: Precision: \leq 3.02 CV%	Precision: Intra-assay CV%: \leq 5.1 Inter-assay CV%: \leq 6.2
Linearity	Up to 100 ng/mL	Up to 500 ng/mL	0 – 300 U/L
Calibration Levels	6-Point Calibration	5-Point Calibration	1-Point Calibration (Lyophilized)
On-Board Stability	Open: Four weeks on board analyzer	Open: One month on board analyzer	Open: Three weeks on board analyzer

1. Zielke K. et al. Fucosidosis: diagnosis by serum assay of α -L-fucosidase. *J. Lab. Clin. Med.* 79: 164 (1972)
2. Giardina MG. et al. Serum α -L-fucosidase. A useful marker in the diagnosis of hepatocellular carcinoma. *Cancer*, 70: 1044 (1992)
3. Ayde D. et al. Value of the serum α -L-fucosidase activity in the diagnosis of colorectal cancer. *Oncology*, 59: 310 (2000)

DIAZYME LABORATORIES

12889 Gregg Court, Poway, CA 92064
PO Box 85608, San Diego, CA 92186
Tel: 858-455-4768 888-DIAZYME

www.diazyme.com sales@diazyme.com

DIAZYME EUROPE GMBH

Zum Windkanal 21, 01109 Dresden, Deutschland
Tel. +49 (0) 351 886 3300 Fax +49 (0) 351 886 3366
sales@diazyme.de

SHANGHAI DIAZYME CO., LTD.

Room 201, 1011 Halei Road, Zhangjiang Hi-tech Park
Shanghai, 201203, People's Republic of China
Tel: 086-21-51320668 Fax: 086-21-51320663
www.lanyuanbio.com service@lanyuanbio.com

